Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.55 |
| ▸ | CA1 | P00915 | 9/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284953 | 0.84 | TP53 (0.62) | CA2CA1CA9CA7CA12 | |
| SCHEMBL6280187 | 0.77 | TP53 (0.62) | CA2CA1CA9CA7CA12 | |
| SCHEMBL678390 | 0.73 | CA2 (1.00) | CA2CA1CA9CA7CA12 | |
| SCHEMBL5677882 | 0.73 | CA2 (0.88) | CA2CA1CA9CA7CA12 | |
| SCHEMBL6280127 | 0.72 | CA2 (0.60) | CA2CA1CA9CA7CA12 | |
| SCHEMBL8353562 | 0.71 | F7 (0.49) | EPHX2NR1H4ALDH1A1 | |
| SCHEMBL6282613 | 0.71 | MEN1 (0.52) | CA2CA1CA9CA12TP53 | |
| SCHEMBL672160 | 0.71 | CA2 (1.00) | CA2CA1CA9CA7CA12 | |
| SCHEMBL13379248 | 0.71 | CA2 (0.85) | CA2CA1CA9CA7CA12 | |
| SCHEMBL11821460 | 0.70 | HPGD (0.71) | CA2CA1CA9RORCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | CA2 2245/4885CA1 4304/4885CA9 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.